Frazier Life Sciences Management, LP
SEC-registered investment adviser.
- Website
- https://www.frazierls.com
- HQ
- CA
Frazier Life Sciences Management is a longstanding healthcare investment firm that partners with and builds companies developing novel therapeutics from seed stage through public markets. It focuses on early-stage private biopharmaceutical companies, with an emphasis on company creation and Series A investments. Its portfolio includes Krystal Biotech, a gene therapy company, and Callio Therapeutics, which develops antibody-drug conjugate therapies.
01 · Says / Does
| Tag | Says | Does |
|---|---|---|
| Stages | Seed, Series A, Growth | Not enough dated deals |
| Sectors | Biotech | Not enough dated deals |
| Regions | Global | Not enough dated deals |
Says: what the firm's funds state. Does: from 0 dated deals in the last 24 months.
02 · Fund history
| Fund | Year | Size | Status |
|---|---|---|---|
| Frazier Life Sciences XII, L.P. | approx. 2025 | Not reported | Raising |
| Frazier Life Sciences XI, L.P. Frazier Life Sciences backs early-stage private biopharmaceutical companies developing novel therapeutics, with an emphasis on company creation and Series A investments, often building product-focused companies and partnering with management over the long term. Inferred from the firm's website | 2022 | $960M (Form D) | Late investment period |
03 · People across funds
- Daniel Estes, Member of the General Partner of the General Partner
Frazier Life Sciences XII, L.P. (Named on Form D); Frazier Life Sciences XI, L.P. (Named on Form D)
- James Topper, Member of the General Partner of the General Partner
Frazier Life Sciences XII, L.P. (Named on Form D); Frazier Life Sciences XI, L.P. (Named on Form D)
- Patrick Heron, Member of the General Partner of the General Partner
Frazier Life Sciences XII, L.P. (Named on Form D); Frazier Life Sciences XI, L.P. (Named on Form D)
- Aditya Kohli, Ph.D., Partner
- Albert Cha, M.D., Ph.D., Managing Partner
- Anna H. Chen, Ph.D., Partner
- Daniel Estes, Ph.D., General Partner
- James N. Topper, M.D., Ph.D., Managing Partner
- James W. Brush, M.D., General Partner and Portfolio Manager
- Joe Cabral, Partner
- Kevin Li, M.D., Partner
- Adam Simpson, Executive Partner
On the team page, not linked to a fund
- Angel Martin, Ph.D., Vice President
On the team page, not linked to a fund
- Christopher Aakre, Ph.D., Principal of Company Creation
On the team page, not linked to a fund
- James Li, M.D., Venture Partner
On the team page, not linked to a fund
- Kiah Williams, M.D., Vice President
On the team page, not linked to a fund
- Lauren Mifflin, Ph.D., Principal of Company Creation
On the team page, not linked to a fund
- Lin Mu, M.D., MBA, Vice President
On the team page, not linked to a fund
- Mansi Shinde, Vice President of Company Creation
On the team page, not linked to a fund
- Maria Fardis, Ph.D., Venture Partner
On the team page, not linked to a fund
- Nirav Shah, M.D., Senior Associate
On the team page, not linked to a fund
- Ryan Peer, Associate
On the team page, not linked to a fund
- Stanford Peng, M.D., Ph.D., Venture Partner
On the team page, not linked to a fund
- Sukh Bansal, Associate
On the team page, not linked to a fund
- Tao Fu, M.S., MBA, Venture Partner
On the team page, not linked to a fund
- Xinghuo Li, Ph.D., Senior Associate
On the team page, not linked to a fund
04 · Recent deals
No dated deals found yet.
05 · Latest from the firm
No news from the firm's website yet.
06 · Sources
- https://www.frazierls.com
- https://frazierls.com/portfolio/
- https://frazierls.com/
- https://frazierls.com/team/
- https://frazierls.com/news/
Fund dates and sizes are from SEC Form D filings.
Last verified: Oct 28, 2026